Carlisle Companies Inc (CSL)

105.72
1.28 1.20
NYSE : Consumer Goods
Prev Close 107.00
Open 106.44
Day Low/High 105.68 / 107.02
52 Wk Low/High 75.17 / 109.13
Volume 431.10K
Avg Volume 423.00K
Exchange NYSE
Shares Outstanding 64.19M
Market Cap 6.82B
EPS 4.90
P/E Ratio 20.13
Div & Yield 1.20 (1.10%)

Latest News

CSL Behring To Present New Data For IDELVION® And AFSTYLA® At The World Federation Of Hemophilia 2016 World Congress

CSL Behring To Present New Data For IDELVION® And AFSTYLA® At The World Federation Of Hemophilia 2016 World Congress

Abstracts include pivotal efficacy and safety data for IDELVION for hemophilia B and AFSTYLA for hemophilia A; AFSTYLA and IDELVION demonstrate CSL Behring's promise to develop and deliver innovative treatments that help patients with serious medical conditions live full lives

U.S. FDA Approves CSL Behring's Berinert® As The First And Only Pediatric Treatment For Hereditary Angioedema (HAE)

U.S. FDA Approves CSL Behring's Berinert® As The First And Only Pediatric Treatment For Hereditary Angioedema (HAE)

Berinert is the only C1 Esterase Inhibitor concentrate approved for on-demand treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) attacks in adult and pediatric patients.

Seqirus Is First-to-market With Shipment Of Seasonal Influenza Vaccines To The US For The 2016-2017 Season

Seqirus Is First-to-market With Shipment Of Seasonal Influenza Vaccines To The US For The 2016-2017 Season

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Carlisle Companies To Announce 2nd Quarter Results On July 26, 2016

Carlisle Companies To Announce 2nd Quarter Results On July 26, 2016

Carlisle Companies Incorporated (NYSE:CSL) will release second quarter 2016 results on Tuesday, July 26, 2016 before the market opens.

CSL Behring Announces Immunoglobulin Research Grant Winners

CSL Behring Announces Immunoglobulin Research Grant Winners

2016 Interlaken Leadership Awards to Advance Neurological Disorders Research

AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy For Hemophilia A - Now Available In The U.S.

AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy For Hemophilia A - Now Available In The U.S.

AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available

Short Interest In Carlisle Companies Moves 38.3% Higher

Short Interest In Carlisle Companies Moves 38.3% Higher

The most recent short interest data has been released for the 05/31/2016 settlement date, which shows a 462,715 share increase in total short interest for Carlisle Companies Inc. , to 1,670,050, an increase of 38.33% since 05/13/2016.

Carlisle Acquires Micro-Coax

Carlisle Acquires Micro-Coax

Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Micro-Coax, Inc.

Today's Weak On High Volume Stock: Carlisle Companies (CSL)

Today's Weak On High Volume Stock: Carlisle Companies (CSL)

Trade-Ideas LLC identified Carlisle Companies (CSL) as a weak on high relative volume candidate

Carlisle Companies To Present At KeyBanc's Conference In Boston June 1

Carlisle Companies To Present At KeyBanc's Conference In Boston June 1

D. Christian "Chris" Koch, President and Chief Executive Officer of Carlisle Companies Incorporated (NYSE:CSL), will be conducting a General Session at KeyBanc's Conference at the InterContinental Hotel in Boston, MA at...

U.S. FDA Approves CSL Behring's AFSTYLA® -- The First And Only Recombinant Factor VIII Single Chain Therapy For Hemophilia A

U.S. FDA Approves CSL Behring's AFSTYLA® -- The First And Only Recombinant Factor VIII Single Chain Therapy For Hemophilia A

- AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available

Carlisle Appoints Kevin P. Zdimal Vice President Of Business Development; Carlisle Appoints Titus B. Ball Vice President And Chief Accounting Officer

Carlisle Appoints Kevin P. Zdimal Vice President Of Business Development; Carlisle Appoints Titus B. Ball Vice President And Chief Accounting Officer

Carlisle Companies Incorporated (NYSE:CSL) announced today the appointment of Kevin P.

CSL's Paul Perreault Receives Healthcare CEO Enterprise Award From Philadelphia Alliance For Capital And Technologies

CSL's Paul Perreault Receives Healthcare CEO Enterprise Award From Philadelphia Alliance For Capital And Technologies

The award recognizes Perreault's leadership, vision and his role in strengthening and promoting the life sciences industry in the region.

Seqirus Honored With National Award For Outstanding Efforts In Influenza Prevention

Seqirus Honored With National Award For Outstanding Efforts In Influenza Prevention

#KnockOutFlu Campaign Drove Home the Importance of Flu Vaccination Among College Students

Jim Cramer's 'Mad Money' Recap: These Stocks Have Staying Power

Jim Cramer's 'Mad Money' Recap: These Stocks Have Staying Power

Staying power is underrated by traders but is the lifeblood of long-term investors, Cramer says.

Carlisle Companies To Present At Oppenheimer Conference In New York City May 10

Carlisle Companies To Present At Oppenheimer Conference In New York City May 10

D. Christian "Chris" Koch, President and Chief Executive Officer of Carlisle Companies Incorporated (NYSE:CSL), will be presenting at Oppenheimer's 11 th Annual Industrial Growth Conference at the Westin Grand Central Hotel...

Carlisle Companies Declares Regular Quarterly Dividend

Carlisle Companies Declares Regular Quarterly Dividend

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.

CSL CEO Paul Perreault Focuses On Patient-Centric Leadership In Pharma

CSL CEO Paul Perreault Focuses On Patient-Centric Leadership In Pharma

-- A successful Pharma of the future requires a much different, authentic form of patient engagement

Trade-Ideas: Carlisle Companies (CSL) Is Today's New Lifetime High Stock

Trade-Ideas: Carlisle Companies (CSL) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified Carlisle Companies (CSL) as a new lifetime high candidate

Carlisle Reports Record First Quarter Earnings Per Share From Continuing Operations Of $1.05, A 78% Increase Over The Prior Year, On Record First Quarter Net Sales

Carlisle Reports Record First Quarter Earnings Per Share From Continuing Operations Of $1.05, A 78% Increase Over The Prior Year, On Record First Quarter Net Sales

Carlisle Companies, Incorporated (NYSE:CSL) reported record first quarter net sales from continuing operations of $794.

CSL Behring Commemorates 100 Years Of Delivering On Its Promise To Develop Innovative Therapies For People With Life-threatening Medical Conditions

CSL Behring Commemorates 100 Years Of Delivering On Its Promise To Develop Innovative Therapies For People With Life-threatening Medical Conditions

- Locally, Company donates 100 trees to Valley Forge National Historical Park to mark centennial anniversary

CSL Behring Marks World Hemophilia Day By Donating IUs Of Its Specialty Biotherapeutics For Bleeding Disorders To World Federation Of Hemophilia

CSL Behring Marks World Hemophilia Day By Donating IUs Of Its Specialty Biotherapeutics For Bleeding Disorders To World Federation Of Hemophilia

- More than 1.5 million international units (IUs) of treatments for hemophilia A and/or von Willebrand Disease shipped in advance of World Hemophilia Day

Carlisle Companies To Announce 1st Quarter Results On April 27, 2016

Carlisle Companies To Announce 1st Quarter Results On April 27, 2016

Carlisle Companies Incorporated (NYSE:CSL) will release first quarter 2016 results on Wednesday, April 27, 2016 before the market opens.

IDELVION® For Hemophilia B Now Available In The U.S.

IDELVION® For Hemophilia B Now Available In The U.S.

-- In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00

CSL Behring Awards LEAD Grants To Help Rare Disease Patient Groups Achieve Their Advocacy Objectives

CSL Behring Awards LEAD Grants To Help Rare Disease Patient Groups Achieve Their Advocacy Objectives

The Community-based Local Empowerment for Advocacy Development (LEAD) Grants will help support initiatives in Indiana, Florida, Tennessee, California and Missouri.

U.S. FDA Approves CSL Behring's IDELVION® -- The First And Only Hemophilia B Therapy With Up To 14-day Dosing Intervals

U.S. FDA Approves CSL Behring's IDELVION® -- The First And Only Hemophilia B Therapy With Up To 14-day Dosing Intervals

- In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00

Carlisle Appoints Amelia Murillo Vice President Of Human Resources

Carlisle Appoints Amelia Murillo Vice President Of Human Resources

Carlisle Companies Incorporated (NYSE:CSL) announced today the appointment of Amelia Murillo to the newly created position of Vice President of Human Resources, effectively immediately.